<DOC>
	<DOCNO>NCT02082691</DOCNO>
	<brief_summary>Patient advance liver cancer ( cancer spread part body ) continue receive study drug ( G-202 ) even though patient long meet criteria part main treatment study . Patient 's cancer respond well receive G-202 main study receive G-202 dose give main study .</brief_summary>
	<brief_title>Continued Administration G-202 One Patient With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>History hepatocellular carcinoma Participation prior research study G202 administer Tolerance G202 treatment Demonstration stable disease Disease progression Occurrence unacceptable toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>G-202</keyword>
	<keyword>Hepatocellular</keyword>
</DOC>